<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study evaluated the association between serum C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels and <z:hpo ids='HP_0011010'>chronic</z:hpo> vascular complications in Korean patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Data for 1,410 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were evaluated cross-sectionally </plain></SENT>
<SENT sid="2" pm="."><plain>Fasting and postprandial 2-hour serum C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels were analyzed with respect to diabetic micro- and macrovascular complications </plain></SENT>
<SENT sid="3" pm="."><plain>In the group of patients with lower fasting serum C-<z:chebi fb="7" ids="16670">peptide</z:chebi> quartile, the prevalences of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> were significantly higher (P = 0.035, P &lt; 0.001, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>In the group of patients with lower delta C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (postprandial - fasting C-<z:chebi fb="7" ids="16670">peptide</z:chebi>) quartile, the prevalences of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> were significantly higher (P &lt; 0.001 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>Low delta C-<z:chebi fb="7" ids="16670">peptide</z:chebi> quartile was also associated with increased severity of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The age- and sex-adjusted odds ratios (ORs) for <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in the lowest versus the highest delta C-<z:chebi fb="7" ids="16670">peptide</z:chebi> quartile were 6.45 (95% confidence interval 3.41-12.22), 3.01 (2.16-4.19), and 2.65 (1.71-4.12), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>After further adjustment for the duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, type of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> therapy, mean <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c, body mass index, and blood pressure, the ORs were reduced to 2.83 (1.32-6.08), 1.68 (1.12-2.53), and 1.61 (1.05-2.47), respectively, but remained significant </plain></SENT>
<SENT sid="8" pm="."><plain>No significant difference was observed in the prevalence of macrovascular complications with respect to fasting or delta C-<z:chebi fb="7" ids="16670">peptide</z:chebi> quartiles </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that low C-<z:chebi fb="7" ids="16670">peptide</z:chebi> level is associated with diabetic microvascular, but not macrovascular complications in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>